This is a phase 2 randomized study for High risk localized prostate cancer (T3 to T4 disease
and/or PSA > 20 and/or Gleason score ≥ 8) without evidence of distant and nodal metastasis.
Patient will be randomized to:Arm 1
- Conventional IMRT RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to
proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common
iliac nodes).
- 38 fractions of daily treatment, Monday to Friday
or Arm 2
SBRT
- RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of
seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)
- 5 fractions of weekly treatment. Once fraction per week. All patients will be given
neoadjuvant and adjuvant androgen deprivation therapy (detail as below)